10 Investor presentation First three months of 2023 Rare disease sales decreased by 1 reduction in manufacturing outp DKK billion 5 -16% Reported Rare disease sales Growth at CER -3% 19% 15% -11% -38% 4 3 Rare blood disorders 2 1 0 Total 1 Rare Haem. Haem. Novo- Rare blood A B Seven ® endocrine disorders 2 disorders 3 1 Total includes “Other Rare disease”, which consists of primarily Vagifem ® and Activelle ® ; 2 Comprises NovoSeven ® , NovoEight ® , Esp CER: Constant exchange rates; Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at con Note: NovoThirteen ® is not shown for Rare blood disorders breakdown, only for the total bar.
Download PDF file